Downloads

  1. April 2025 — CDMO Opportunities And Threats Report 5/8/2025

    Each month, Outsourced Pharma works in conjunction with PharmSource, part of GlobalData, to present its “Contract Manufacturing: Opportunities and Threats (CMOT) Report” to our readers. The report identifies CDMOs that might be impacted by key events affecting their clients, including company acquisitions, product acquisitions and licenses, product approvals, late clinical product terminations, and FDA rejections.

  2. Incorporating AI Tools Into Downstream Process Optimization 5/8/2025

    Data-driven, hybrid modeling complements mechanistic thinking by reducing computational load for faster decision-making when time is a critical consideration.

  3. A Road Map For PAT Monitoring And Control 5/8/2025

    Process analytic technology monitoring and control is rapidly progressing. BioPhorum shares new best practices on how to move from concept through life cycle management and/or regulatory approval of the PAT application.

  4. Is Early Automation The Key To Scalable Cell Therapy Manufacturing? 5/8/2025

    Picking which phase to introduce automation has serious implications, and the calculation is unique for every product. Here are some important considerations.

  5. Hard Lessons In Parenteral Automatic Visual Inspection 5/7/2025

    Complex problems can have simple solutions. That's what a team at AstraZeneca found when they set out to reduce false rejection rates in vials containing mAbs.

  6. The EU Biotech Act Has Been Delayed — Here's What That Means 5/7/2025

    First due at the end of 2025, the act has been delayed until late 2026, which suggests key issues that many say hobble innovation will go unaddressed for longer.

  7. Excellence In Every Injection. 5/7/2025

    We don’t just manufacture sterile injectables — we provide trusted partnership, operational excellence, and a deep commitment to getting life-saving therapies to patients safely, reliably, and on time.

  8. Building A Legacy In Sterile Injectables Through Strong CMO Synergy 5/7/2025

    Examine how a CMO can deliver significant value to drug developers by fostering successful outsourcing relationships, streamlining the path to market, and supporting demands.

  9. From Preparation To Compliance: DSCSA Implementation Takes Big Steps In 2025 5/7/2025

    The phased exemption periods of the Drug Supply Chain Security Act (DSCSA) expire on different dates throughout 2025 (including one quickly approaching in May), marking a series of milestones for implementation.

  10. Drug Product Manufacturing: Scaling Product From Bench To Market 5/7/2025

    Curia offers comprehensive development and manufacturing services to meet needs through the entire lifecycle of your sterile drug product. Leverage our in-depth expertise and capabilities at any scale, from early clinical through large-scale commercial.